|
|
|
|
|
| Premium Lab Equipment Sold At Deep Discount |
|
|
| Strategic partnership focuses on target drug delivery. |
|
|
| Report fuels new calls for increased public warnings about dangers of Pfizer smoking cessation drug Chantix. Deaths and record number of serious injuries reported to FDA. |
|
|
| Hyde Engineering + Consulting Inc. (Hyde E+C) is pleased to announce that Todd McLaren has joined our team as Senior Vice President of Marketing and New Business Development with overall responsibility for the East Coast. Todd's experience in the pharmaceutical and biotechnology industries spans more than 24 years. He has been instrumental in leading engineering and construction companies in supporting the sector. |
|
|
| Sieving is the most widely used technique for determining particle size distribution. The specification of sieve characteristics is shrouded in mystery. This announces a paper that demystifies the sieve definition part of particle size analysis. |
|
|
| Driven by the growing popularity and waxing use of gelatins as biomaterials in cosmetic formulations, and the gradual dissipation of the apprehension concerning animal-sourced gelatin, the world gelatin market is projected to reach 359 thousand metric tons by the year 2012. |
|
|
| Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif® (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab improved from baseline, whereas the mean disability of those on Rebif worsened. The treatment... |
|
|
| Driven by increased outsourcing from cost-pressured, limited pipeline biotech and pharmaceutical companies, the market for pharmaceutical contract manufacturing is projected to exceed $31 billion by 2012. |
|
|
| Contract Research Outsourcing (CRO), which came into being in the seventies, evolved into an essential component of pharmaceutical market scenario. Demand for CRO services is forecast to increase with mounting pressure on pharma and biotech companies to lower costs and augment productivity. World market for Contract Research Outsourcing is projected to exceed $26.2 billion by the year 2012. |
|
|
